---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-008611"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:04:50.120386+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# CervoMed Q4/FY2025 net loss widens to $27M; cash runway ~6 months; Phase 3 DLB trial pending financing

## Summary
- FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.
- FDA alignment obtained for planned Phase 3 DLB trial; initiation in H2 2026 subject to funding.
- Selected 50mg TID neflamapimod dose for Phase 3; additional data to be presented at AD/PD 2026.
- Topline data expected H2 2026 from Phase 2a RAS and nfvPPA trials; ALS trial start by YE 2026.
- Grant revenue fell to $4.0M from $9.7M due to RewinD-LB completion; R&D spend rose to $21.8M.

## SEC filing metadata
- accession: 0001437749-26-008611
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/0001437749-26-008611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/crvo20260317_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-008611
- JSON: https://secwatch.observer/filing/0001437749-26-008611.json
- Plain text: https://secwatch.observer/filing/0001437749-26-008611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.